Cancer Diseases Lifestyle Medicine

Global Gallbladder Cancer Industry 2018 Specification, Growth Drivers, Market Analysis and Industry across 18 Major Markets – 2025 Epiomic Epidemiology Series: Gallbladder Cancer Forecast in 18 Major Markets 2015-2025” report has been added to its Research Database.

Scope of the Report:

The Epidemiology Forecast Report on Gallbladder Cancer in 18 Major Markets 
Gallbladder Cancer (GBC) primarily occurs in the gallbladder itself, but also includes the extrahepatic bile duct, Ampulla of Vater and other non-specified biliary duct tumours. It is currently the most common malignant tumour of the biliary tract worldwide, with a very low survival rate. There are currently no known causes for GBC at this point in time.


This report provides the current incidence population for GBC across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, India, Mexico, Turkey, South Africa, Saudi Arabia, Argentina, Russia and China) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of GBC tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GBC have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Request a Sample Report @

Main symptoms and co-morbidities for GBC include: 

Chronic cholecystitis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy 

Able to quantify patient populations in global GBC’s market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the incidence of the subdivided types of GBC and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on GBC’s prevalent population.

Examination of the incidence of the different causative gene mutations for GBC.

Identify sub-populations within GBC which require treatment.

Gain an understanding of the specific markets that have the largest number of GBC patients.


For Detailed Reading Please visit @

Major Key Points in Table of Content:

List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis &Clinical Course
• Key Co-morbid Conditions /Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
o Additional data available on request
• Top-Line Prevalence for Gout
• Features of Gout Patients Experiencing Flare in Past 12 Months
o Frequency of Flare in past 12 months
o Joint Involvement in Gout patients during Flare
o Kidney Function and Features in patients with Gout
• Features of Gout Patients at Initial Presentation
• Associated Co-morbid Conditions of Gout
• Tophaceous Gout
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix



Contact Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)